Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Inclusion Criteria:

* Age = or \> 18 years Histological or cytological diagnosis of undifferentiated or poorly differentiated nasopharyngeal carcinoma that is locally advanced or metastatic.
* Disease progression either clinically or radiographically after 1-2 previous regimens.
* Patient has received a platinum containing regimen. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Radiographically-documented measureable disease.
* Adequate organ and bone marrow functions.
* Willingness to follow pregnancy precautions.

Exclusion Criteria:

* History of, or current brain metastasis. Any other malignancy within 5 years prior to randomization with the exception of adequately treated in situ carcinoma of the cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed 6 months prior to enrollment), in situ squamous cell carcinoma of the breast, or incidental prostate cancer.
* Previous treatment with azacitidine (any formulation), decitabine, any other hypomethylating agent.
* History of gastrointestinal disorder or defect. Impaired ability to swallow oral medication. Persistent diarrhea or malabsorption.
* Active cardiac disease and human immunodeficiency virus (HIV) infection
* Active bleeding; pathological condition that carries a high risk of bleeding; risk of pseudoaneurysm of the internal carotid artery and carotid blowout syndrome.
* Major surgery within 14 days prior to starting Investigational Product or has not recovered from major side effects.
* Another investigational therapy within 28 days or 5 half lives of randomization/enrollment, whichever is shorter.
* Patient has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.
* Radiotherapy \< or = 4 weeks or limited field radiation for palliation \< or = 2 weeks prior to starting with the investigational product.
* Pregnancy/Breast feeding
* Any condition that places the patient at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.